UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Current and future treatment options in non-alcoholic steatohepatitis (NASH)

Lazaridis, N; Tsochatzis, E; (2017) Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Review of Gastroenterology & Hepatology , 11 (4) pp. 357-369. 10.1080/17474124.2017.1293523. Green open access

[thumbnail of ERGH NASH submitted.pdf]
Preview
Text
ERGH NASH submitted.pdf - Accepted Version

Download (519kB) | Preview

Abstract

INTRODUCTION: Non-alcoholic steatohepatitis (NASH) is a chronic liver disease that can progress to cirrhosis and hepatocellular carcinoma. Diagnosis of NASH requires a liver biopsy and is defined as presence of hepatic steatosis, ballooning and lobular inflammation with or without fibrosis. Although NASH is the most common cause of liver disease in the west world and among the top three indications for liver transplantation, there are no universally accepted pharmacological therapies and therapeutic advances have been slow. AREAS COVERED: Current evidence about lifestyle interventions, bariatric surgery and pharmacotherapy is reviewed. Dietary recommendations and lifestyle interventions have shown promising results but are difficult to maintain. At the moment, there is no universally approved medical treatment for NASH. Pioglitazone and vitamin E are recommended by guidelines in selected patients. An increasing number of phase II and III trials in non-cirrhotic NASH are currently recruiting and their preliminary results discussed. EXPERT COMMENTARY: As NASH is classified as a medical condition of an unmet therapeutic need, it has gained an accelerated access pathway for drug approval based on surrogate endpoints. It is therefore expected that within the next five years, there will be at least one approved agent for the pharmacological treatment of pre-cirrhotic NASH.

Type: Article
Title: Current and future treatment options in non-alcoholic steatohepatitis (NASH)
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1080/17474124.2017.1293523
Publisher version: http://dx.doi.org/10.1080/17474124.2017.1293523
Language: English
Additional information: Copyright © 2017 Taylor & Francis. This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology on 3 April 2017, available online: http://www.tandfonline.com/10.1080/17474124.2017.1293523
Keywords: Fibrosis, bariatric surgery, cirrhosis, elafibranor, fatty liver, obeticholic acid
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inst for Liver and Digestive Hlth
URI: https://discovery.ucl.ac.uk/id/eprint/1545249
Downloads since deposit
828Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item